Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genetic polymorphism of IDOL gene was associated with the susceptibility of coronary artery disease in Han population in Xinjiang, China
Hereditas Open Access 12 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
LaRosa, J. C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
Kastelein, J. J. P. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729–1735 (2006).
Stroes, E. S. et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303–2304 (2008).
Kamstrup, P. R., Tybjærg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–2339 (2009).
Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).
Stein, E. A. et al. Effect of a monoclonal antibodies to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108–1118 (2012).
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).
The TG and HDL Group of the Exome Sequencing Project, National, Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary heart disease. N. Engl. J. Med. 371, 22–31 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.J.P.K. declares that he has acted as a consultant and received honouraria from the following companies: Aegerion, Amgen, AstraZeneca, Atheronova, Boehringer Ingelheim, Catabasis, Cerenis, CSL Behring, Dezima Pharmaceuticals, Eli Lilly, Esperion, Genzyme, Isis, Merck, Novartis, Omthera, Pronova, Regeneron, Sanofi, The Medicines Company, UniQure, and Vascular Biogenics.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kastelein, J. Resurgence of targets and compounds to treat dyslipidaemia. Nat Rev Cardiol 11, 629–631 (2014). https://doi.org/10.1038/nrcardio.2014.132
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.132
This article is cited by
-
Genetic polymorphism of IDOL gene was associated with the susceptibility of coronary artery disease in Han population in Xinjiang, China
Hereditas (2021)
-
Targeting ApoC-III to Reduce Coronary Disease Risk
Current Atherosclerosis Reports (2016)
